Montelukast Viatris (Montelukast)

Montelukast blocks the cysteinyl leukotriene receptor CysLT1, preventing leukotrienes from causing airway smooth‑muscle contraction, mucus production, and inflammatory cell recruitment. This inhibition reduces bronchoconstriction and airway inflammation, improving breathing and nasal symptoms.

The appropriate dose of Montelukast Viatris is determined by the prescribing healthcare professional based on the patient’s age, weight, severity of disease, and clinical response. No fixed regimen is provided here; the prescriber sets the exact dosage.

Safety data for Montelukast in pregnancy are limited, and the product is classified as pregnancy category unknown. It should be used only if the potential benefit justifies the potential risk. During breastfeeding, it is unclear whether the drug is excreted in milk; clinicians should weigh benefits against possible risks.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids or long‑acting beta‑agonists. It is particularly useful for patients with aspirin‑sensitive asthma or those who need additional control of allergic symptoms, but it does not replace rescue bronchodilators for acute attacks.

Montelukast Viatris should be stored at ambient temperature, below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and store them out of reach of children.

Montelukast Viatris is taken orally, usually as a tablet swallowed whole with water. The exact timing (e.g., morning or evening) and whether it should be taken with food are determined by the prescribing clinician.

Serious risks include severe allergic reactions such as angioedema or anaphylaxis, neuropsychiatric events like mood changes, depression or suicidal thoughts, and rare hepatic injury. Patients should seek immediate medical attention if they experience any of these symptoms.

Montelukast Viatris is contraindicated in individuals with known hypersensitivity to montelukast or any of its excipients. Caution is advised for patients with severe hepatic impairment, and it should be avoided in those taking strong enzyme‑inducing drugs without appropriate monitoring.